Pharmacia Xalatan first-line use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharmacia gains a first-line indication for its prostaglandin eye drop Xalatan (latanoprost) Dec. 20 for the initial treatment of elevated eye pressure associated with open-angle glaucoma or ocular hypertension. The upgrade from second-line treatment was based on five-year safety data, the firm says. First-line use was originally rejected due to FDA's concerns about iris and eyelid pigmentatio